VEGFA and retinal disorder: As an adjuvant to cytostatic drugs in animal tumor models [14,152,164,165,166]; as a monotherapy in animal retinopathy models [167,168,169]; squalamine lactate as monotherapy or in combination with mAb to VEGF in phase 2 clinical trilas for age-related macular edema [210,211,212,213,214]; combinatorial therapy in phase 2 clinical trilas for non-small cell lung cancer [210,211,212]